Literature DB >> 31098748

Extrastriatal dopaminergic and serotonergic pathways in Parkinson's disease and in dementia with Lewy bodies: a 123I-FP-CIT SPECT study.

Andrea Pilotto1,2, Francesca Schiano di Cola3, Enrico Premi3,4, Roberto Grasso3, Rosanna Turrone3, Stefano Gipponi3, Andrea Scalvini3, Elisabetta Cottini3, Barbara Paghera5, Valentina Garibotto6, Maria Cristina Rizzetti7, Laura Bonanni8, Barbara Borroni3, Silvia Morbelli9,10, Flavio Nobili10,11, Ugo Paolo Guerra12, Daniela Perani13, Alessandro Padovani3.   

Abstract

PURPOSE: The aim of the study was to evaluate extrastriatal dopaminergic and serotonergic pathways in patients with Parkinson's disease (PD) and dementia with Lewy bodies (DLB) using 123I-FP-CIT SPECT imaging.
METHODS: The study groups comprised 56 PD patients without dementia, 41 DLB patients and 54 controls. Each patient underwent a standardized neurological examination and 123I-FP-CIT SPECT. Binding in nigrostriatal and extrastriatal regions of interest was calculated in each patient from spatially normalized images. The occipital-adjusted specific to nondisplaceable binding ratio (SBR) in the different regions was compared among the PD patients, DLB patients and controls adjusting for the effects of age, sex, disease duration and serotonergic/dopaminergic treatment. Covariance analysis was used to determine the correlates of local and long-distance regions with extrastriatal 123I-FP-CIT deficits.
RESULTS: Both PD and DLB patients showed lower 123I-FP-CIT SPECT SBR in several regions beyond the nigrostriatal system, especially the insula, cingulate and thalamus. DLB patients showed significantly lower 123I-FP-CIT SBR in the thalamus than controls and PD patients. Thalamic and cingulate 123I-FP-CIT SBR deficits were correlated, respectively, with limbic serotonergic and widespread cortical monoaminergic projections only in DLB patients but exhibited only local correlations in PD patients and controls.
CONCLUSION: PD and DLB patients both showed insular dopamine deficits, whereas impairment of thalamic serotonergic pathways was specifically associated with DLB. Longitudinal studies are necessary to determine the clinical value of the assessment of extrastriatal 123I-FP-CIT SPECT.

Entities:  

Keywords:  123I-FP-CIT SPECT; Dementia with Lewy bodies; Dopamine; Parkinson’s disease; Serotonin

Mesh:

Substances:

Year:  2019        PMID: 31098748     DOI: 10.1007/s00259-019-04324-5

Source DB:  PubMed          Journal:  Eur J Nucl Med Mol Imaging        ISSN: 1619-7070            Impact factor:   9.236


  50 in total

1.  Automated Talairach atlas labels for functional brain mapping.

Authors:  J L Lancaster; M G Woldorff; L M Parsons; M Liotti; C S Freitas; L Rainey; P V Kochunov; D Nickerson; S A Mikiten; P T Fox
Journal:  Hum Brain Mapp       Date:  2000-07       Impact factor: 5.038

2.  Insular pathology in Parkinson's disease patients with orthostatic hypotension.

Authors:  Spiridon Papapetropoulos; Deborah C Mash
Journal:  Parkinsonism Relat Disord       Date:  2006-09-07       Impact factor: 4.891

3.  Does striatal pathology distinguish Parkinson disease with dementia and dementia with Lewy bodies?

Authors:  Kurt A Jellinger; Johannes Attems
Journal:  Acta Neuropathol       Date:  2006-06-28       Impact factor: 17.088

4.  Dopamine transporter immunoreactivity in monkey cerebral cortex: regional, laminar, and ultrastructural localization.

Authors:  D A Lewis; D S Melchitzky; S R Sesack; R E Whitehead; S Auh; A Sampson
Journal:  J Comp Neurol       Date:  2001-03-26       Impact factor: 3.215

5.  The application of statistical parametric mapping to 123I-FP-CIT SPECT in dementia with Lewy bodies, Alzheimer's disease and Parkinson's disease.

Authors:  Sean J Colloby; John T O'Brien; John D Fenwick; Michael J Firbank; David J Burn; Ian G McKeith; E David Williams
Journal:  Neuroimage       Date:  2004-11       Impact factor: 6.556

6.  Quantification of striatal dopamine transporters with 123I-FP-CIT SPECT is influenced by the selective serotonin reuptake inhibitor paroxetine: a double-blind, placebo-controlled, crossover study in healthy control subjects.

Authors:  Jan Booij; Jan de Jong; Kora de Bruin; Remco Knol; Maartje M L de Win; Berthe L F van Eck-Smit
Journal:  J Nucl Med       Date:  2007-03       Impact factor: 10.057

7.  Striatal dopamine transporter in dementia with Lewy bodies and Parkinson disease: a comparison.

Authors:  Z Walker; D C Costa; R W H Walker; L Lee; G Livingston; E Jaros; R Perry; I McKeith; C L E Katona
Journal:  Neurology       Date:  2004-05-11       Impact factor: 9.910

Review 8.  Diagnosis and management of dementia with Lewy bodies: third report of the DLB Consortium.

Authors:  I G McKeith; D W Dickson; J Lowe; M Emre; J T O'Brien; H Feldman; J Cummings; J E Duda; C Lippa; E K Perry; D Aarsland; H Arai; C G Ballard; B Boeve; D J Burn; D Costa; T Del Ser; B Dubois; D Galasko; S Gauthier; C G Goetz; E Gomez-Tortosa; G Halliday; L A Hansen; J Hardy; T Iwatsubo; R N Kalaria; D Kaufer; R A Kenny; A Korczyn; K Kosaka; V M Y Lee; A Lees; I Litvan; E Londos; O L Lopez; S Minoshima; Y Mizuno; J A Molina; E B Mukaetova-Ladinska; F Pasquier; R H Perry; J B Schulz; J Q Trojanowski; M Yamada
Journal:  Neurology       Date:  2005-10-19       Impact factor: 9.910

9.  The basal ganglia matching tools package for striatal uptake semi-quantification: description and validation.

Authors:  Piero Calvini; Guido Rodriguez; Fabrizio Inguglia; Alessandro Mignone; Ugo Paolo Guerra; Flavio Nobili
Journal:  Eur J Nucl Med Mol Imaging       Date:  2007-02-08       Impact factor: 10.057

Review 10.  Clinical diagnostic criteria for dementia associated with Parkinson's disease.

Authors:  Murat Emre; Dag Aarsland; Richard Brown; David J Burn; Charles Duyckaerts; Yoshikino Mizuno; Gerald Anthony Broe; Jeffrey Cummings; Dennis W Dickson; Serge Gauthier; Jennifer Goldman; Christopher Goetz; Amos Korczyn; Andrew Lees; Richard Levy; Irene Litvan; Ian McKeith; Warren Olanow; Werner Poewe; Niall Quinn; Christina Sampaio; Eduardo Tolosa; Bruno Dubois
Journal:  Mov Disord       Date:  2007-09-15       Impact factor: 10.338

View more
  7 in total

1.  AAV-Mediated Expression of Dominant-Negative ULK1 Increases Neuronal Survival and Enhances Motor Performance in the MPTP Mouse Model of Parkinson's Disease.

Authors:  Dirk Balke; Lars Tatenhorst; Vivian Dambeck; Vinicius Toledo Ribas; Björn F Vahsen; Uwe Michel; Mathias Bähr; Paul Lingor
Journal:  Mol Neurobiol       Date:  2019-08-24       Impact factor: 5.590

2.  Imaging Dopaminergic Neurotransmission in Neurodegenerative Disorders.

Authors:  Elon D Wallert; Elsmarieke van de Giessen; Remco J J Knol; Martijn Beudel; Rob M A de Bie; Jan Booij
Journal:  J Nucl Med       Date:  2022-06       Impact factor: 11.082

3.  Processing speed is related to striatal dopamine transporter availability in Parkinson's disease.

Authors:  Chris Vriend; Tim D van Balkom; Corné van Druningen; Martin Klein; Ysbrand D van der Werf; Henk W Berendse; Odile A van den Heuvel
Journal:  Neuroimage Clin       Date:  2020-04-21       Impact factor: 4.881

4.  Data-driven identification of diagnostically useful extrastriatal signal in dopamine transporter SPECT using explainable AI.

Authors:  Mahmood Nazari; Andreas Kluge; Ivayla Apostolova; Susanne Klutmann; Sharok Kimiaei; Michael Schroeder; Ralph Buchert
Journal:  Sci Rep       Date:  2021-11-25       Impact factor: 4.379

5.  Extrastriatal 123I-FP-CIT SPECT impairment in Parkinson's disease - the PPMI cohort.

Authors:  Nicolas Nicastro; Valentina Garibotto; Pierre R Burkhard
Journal:  BMC Neurol       Date:  2020-05-16       Impact factor: 2.474

6.  Imaging of dopamine transporters in Parkinson disease: a meta-analysis of 18 F/123 I-FP-CIT studies.

Authors:  Yanyan Kong; Chencheng Zhang; Kawai Liu; Aparna Wagle Shukla; Bomin Sun; Yihui Guan
Journal:  Ann Clin Transl Neurol       Date:  2020-08-14       Impact factor: 4.511

7.  A multicentre validation study of the diagnostic value of plasma neurofilament light.

Authors:  Nicholas J Ashton; Shorena Janelidze; Ahmad Al Khleifat; Antoine Leuzy; Emma L van der Ende; Thomas K Karikari; Andrea L Benedet; Tharick A Pascoal; Alberto Lleó; Lucilla Parnetti; Daniela Galimberti; Laura Bonanni; Andrea Pilotto; Alessandro Padovani; Jan Lycke; Lenka Novakova; Markus Axelsson; Latha Velayudhan; Gil D Rabinovici; Bruce Miller; Carmine Pariante; Naghmeh Nikkheslat; Susan M Resnick; Madhav Thambisetty; Michael Schöll; Gorka Fernández-Eulate; Francisco J Gil-Bea; Adolfo López de Munain; Ammar Al-Chalabi; Pedro Rosa-Neto; Andre Strydom; Per Svenningsson; Erik Stomrud; Alexander Santillo; Dag Aarsland; John C van Swieten; Sebastian Palmqvist; Henrik Zetterberg; Kaj Blennow; Abdul Hye; Oskar Hansson
Journal:  Nat Commun       Date:  2021-06-07       Impact factor: 14.919

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.